Scott L. Burrows - 02 Sep 2025 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Issuer symbol
SYRE
Transactions as of
02 Sep 2025
Net transactions value
-$299,639
Form type
4
Filing time
03 Sep 2025, 18:53:19 UTC
Previous filing
17 Jan 2025
Next filing
13 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Burrows Scott L Chief Financial Officer 221 CRESCENT STREET, BUILDING 23,, SUITE 105, WALTHAM /s/ Heidy King-Jones, as Attorney-in-Fact 03 Sep 2024 0001853327

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRE Common Stock Sale $299,639 -18,428 -16% $16.26 97,994 02 Sep 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported reflects the sale of shares of common stock, par value $0.0001 per share, of the Issuer ("Common Stock") in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,738 restricted stock units ("RSUs"). This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade made by the Reporting Person.
F2 The price reported is a weighted average sale price of the Common Stock. These shares were sold in multiple transactions at prices ranging from $16.26 to $16.30, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Includes 67,476 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.